Hyperacusis (Phonophobia)

Subscribe to Selected New Research on Hyperacusis

107 relevant articles (24 outcomes, 11 trials/studies) found for this Disease

Description: An abnormally disproportionate increase in the sensation of loudness in response to auditory stimuli of normal volume. COCHLEAR DISEASES; VESTIBULOCOCHLEAR NERVE DISEASES; FACIAL NERVE DISEASES; STAPES SURGERY; and other disorders may be associated with this condition.

Also Known As:

Phonophobia; Hyperacusia; Loudness Perception Disturbances; Auditory Hyperesthesias; Disturbance, Loudness Perception; Disturbances, Loudness Perception; Hyperacuses; Hyperacusias; Hyperesthesia, Auditory; Hyperesthesias, Auditory; Loudness Perception Disturbance; Loudness Recruitments; Perception Disturbance, Loudness; Perception Disturbances, Loudness; Phonophobias; Auditory Hyperesthesia; Loudness Recruitment; Recruitment, Loudness

Relationship Network

Disease Context: Research Results

Otorhinolaryngologic Diseases: 123

Ear Diseases: 115

Hearing Disorders: 179

Hyperacusis: 107

Nervous System Diseases: 3406

Neurologic Manifestations: 2876

Sensation Disorders: 47

Hearing Disorders: 179

Hyperacusis: 107

Signs and Symptoms Pathological Conditions

Signs and Symptoms

Neurologic Manifestations: 2876

Sensation Disorders: 47

Hearing Disorders: 179

Hyperacusis: 107

Related Diseases

1.	Photophobia (Light Sensitivity)
2.	Nausea
3.	Migraine Disorders (Migraine)
4.	Pain (Aches)
5.	Vomiting
20 Diseases and 87 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Experts

1.	Mir-Salim, P A: 1 article (04/2001)
2.	Stange, T: 1 article (04/2001)
3.	Berghaus, A: 1 article (04/2001)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hyperacusis:

1.	Sumatriptan (Imigran)FDA Link 11/01/2000 - "Photophobia and phonophobia were significantly reduced 2 hours postdose for sumatriptan NS (20 mg), compared with placebo (36% vs 48% and 25% vs 44%, respectively)" 03/01/1998 - "Sumatriptan (all doses) was similarly effective at relieving nausea and photophobia or phonophobia or both and at reducing clinical disability" 04/17/1995 - "Resolution of nausea, photophobia and phonophobia was significantly more common in patients on sumatriptan than on placebo (p < 0.001 for all comparisons)" 08/01/1994 - "Resolution of nausea, photophobia, and phonophobia was significantly more common in patients on sumatriptan than in those on placebo (p < 0.001 for all comparisons)" 01/01/2001 - "In placebo-controlled clinical trials, sumatriptan, administered subcutaneously, orally, intranasally or rectally was significantly more effective than placebo in relieving migraine headache and in producing relief or resolution of other symptoms associated with migraine, including nausea, photophobia and phonophobia" Get all the results and reference details, order at left...
2.	zolmitriptan (Zomig)FDA Link 10/01/1997 - "Zolmitriptan reduced the incidence of nausea, photophobia and phonophobia, reduced impairment of normal activity and demonstrated positive effects on patients' quality of life" 01/01/2005 - "Zolmitriptan ODT relieved patients of other migraine-associated symptoms, including nausea, photophobia and phonophobia, and enabled >50% of patients to resume normal daily activities 2 hours after dosing" 07/01/2002 - "Migraine-associated symptoms, including nausea, photophobia and phonophobia, are also improved with zolmitriptan" 11/01/1997 - "Also, zolmitriptan effectively relieved migraine-associated symptoms such as nausea, photophobia and phonophobia, and reduced activity impairment" 08/01/1999 - "Other symptoms of migraine, including nausea, photophobia and phonophobia are also alleviated with zolmitriptan" Get all the results and reference details, order at left...
3.	Acetaminophen (Paracetamol)FDA LinkGeneric 12/11/2000 - "At 2 hours, other migraine headache characteristics, such as functional disability (P =.002), photophobia (P =.02), and phonophobia (P =.08), were significantly improved after treatment with acetaminophen vs placebo" 12/11/2000 - "CONCLUSIONS: Acetaminophen was highly effective for treating pain, functional disability, photophobia, and phonophobia in a population-based sample of persons with migraine, excluding the most disabled persons with migraine" 11/01/2005 - "Two hours after dosing, moderate-to-severe symptoms that were less common for tramadol/APAP than placebo included photophobia (34.6% vs. 52.2%, P= .003) and phonophobia (34.3% vs. 44.9%, P = .008), but not migraine-related nausea (38.5% vs. 29.4%, P= .681)" 11/01/2005 - "CONCLUSIONS: Tramadol/APAP reduces the severity of pain, photophobia, and phonophobia associated with migraine headache, but does not reduce migraine-associated nausea" 02/01/1998 - "Other migraine headache characteristics, such as nausea, photophobia, phonophobia, and functional disability, were significantly improved 2 to 6 hours after treatment with the acetaminophen, aspirin, and caffeine combination compared with placebo (P< or =.01)" Get all the results and reference details, order at left...
4.	almotriptan (Axert)FDA Link 02/01/2007 - "At 2 to 4 hours and 4 to 24 hours after treatment, the mean intensity of phonophobia and photophobia were significantly lower in the patients treated with almotriptan compared to the placebo-treated patients" 10/01/2008 - "Age group subanalysis demonstrated significantly greater 2-hour pain-relief rates with all 3 doses of almotriptan compared with placebo for patients aged 15 to 17 years, a significantly lower incidence of photophobia and phonophobia at 2 hours with almotriptan 12.5 mg compared with placebo for patients aged 15 to 17 years, and a significantly lower incidence of photophobia with almotriptan 12.5 mg compared with placebo for those aged 12 to 14 years" 01/01/2002 - "RESULTS: The incidence of nausea, photophobia, and phonophobia at 2 hours after dosing with study medication was significantly reduced (all P <.05) with almotriptan 6.25 mg or 12.5 mg compared with placebo" 10/01/2008 - "The incidence of nausea, photophobia, and phonophobia at 2 hours (adjusted for baseline pain intensity) for the almotriptan 25 mg and placebo groups was not significantly different" 01/01/2002 - "Other symptoms of migraine, including nausea, photophobia and phonophobia, are also alleviated by almotriptan" Get all the results and reference details, order at left...
5.	Valproic Acid (Valproate, Semisodium)FDA LinkGeneric 07/01/2004 - "Including additionally 3 patients on placebo and 1 patient on valproate who felt they had suffered a migraine attack, but who had as associated symptoms only photophobia or phonophobia, a significant reduction in the number of patients with induced migraine after valproate was seen (P = 0.031)" 11/01/2001 - "Intravenous valproate and intramuscular dihydroergotamine provided similar relief from associated migrainous symptoms (nausea, photophobia, and phonophobia) during the first 4 hours following treatment" Get all the results and reference details, order at left...
6.	alginic acid compound (AAC)FDA Link 09/01/1999 - "The proportion of subjects reporting improvement in functional disability, photophobia, and phonophobia was significantly greater for AAC than placebo from 2 h through 6 h postdose" 03/01/1999 - "Migraine characteristics such as photophobia, phonophobia, and functional disability were significantly improved in AAC-treated subjects at all time points from 1 through 6 hours (P< or =0.01) in both the menstruating and nonmenstruating groups" Get all the results and reference details, order at left...
7.	Pain-FreeIBA 03/11/2004 - "Significant superiority over placebo was also observed with respect to most secondary end points: the pain-free rate at 2 hours; the rate of sustained response over a period of 24 hours; the rate of recurrence of headache; improvement in nausea, photophobia, phonophobia, and functional capacity; and the time to meaningful relief" 01/01/2001 - "The clinically recommended dose is 2.5 mg. It was found significantly superior to placebo on headache relief and pain free at 2 and 4 hours, and in relieving nausea, photophobia and phonophobia" 01/01/2008 - "Multivariate regression analyses identified three significant baseline predictors of failure to achieve 2-h pain-free response: severe headache pain, presence of photophobia/phonophobia and presence of nausea" 11/01/2005 - "Other efficacy end points included the proportion of patients who were migraine free (ie, no pain and no associated symptoms of nausea, vomiting, photophobia, or phonophobia) 2 hours postdose; the proportion reporting worsening of pain (ie, moderate or severe pain) 2 hours postdose; and the proportion with a sustained pain-free result (ie, pain free from 2-24 hours postdose with no use of a second dose of study medication or of rescue medication)" 10/23/2001 - "OUTCOME MEASURES: Percentage of patients pain-free at 2 hours, symptom-free at 2 hours (no pain, nausea, photophobia, phonophobia, vomiting, or functional disability), 24-hour sustained pain-free (no headache at 2 hours, no recurrence, and no additional antimigraine medications for 24 hours)" Get all the results and reference details, order at left...
8.	Caffeine (No Doz)FDA LinkGeneric 03/01/2007 - "Almotriptan was associated with a significantly lower rate of photophobia at 90 min (P < 0.05), phonophobia at 60, 90, and 120 min (P < 0.05 to <0.01), and nausea and vomiting at 90 and 120 min (P < 0.01) compared with ergotamine plus caffeine" 01/01/2003 - "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001)" 02/01/1998 - "Other migraine headache characteristics, such as nausea, photophobia, phonophobia, and functional disability, were significantly improved 2 to 6 hours after treatment with the acetaminophen, aspirin, and caffeine combination compared with placebo (P< or =.01)" 02/01/1998 - "CONCLUSIONS: The nonprescription combination of acetaminophen, aspirin, and caffeine was highly effective for the treatment of migraine headache pain as well as for alleviating the nausea, photophobia, phonophobia, and functional disability associated with migraine attacks" 06/01/1999 - "Effects on phonophobia or photophobia did not differ between diclofenac-potassium, sumatriptan and ergotamine plus caffeine" Get all the results and reference details, order at left...
9.	rizatriptan (Maxalt)FDA Link 03/01/2001 - "At 2 h, rizatriptan 10 mg was significantly more effective than placebo for pain relief (71% vs. 38%, P < 0.001), and for elimination of pain, nausea, photophobia, phonophobia and functional disability" 01/01/2001 - "Rizatriptan was also superior to sumatriptan in terms of the proportions of patients with no nausea, phonophobia or photophobia, and patients with normal function 2 h after treatment intake (p < 0.05)" 11/28/2000 - "RESULTS: Of the evaluable patients who treated three migraine attacks with 10 mg of rizatriptan (with an additional interspersed placebo-treated attack in most patients), 216 of 252 (86%) had pain relief (reduction of pain to mild or none), 122 of 252 (48%) were pain free, 211 of 250 (84%) had no nausea, 163 of 251 (65%) had no photophobia, 182 of 252 (72%) had no phonophobia, 136 of 249 (55%) had no functional disability, and 233 of 252 (92%) had no need for escape medications at 2 hours after dosing in at least two of three attacks" 01/01/2003 - "Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001)" Get all the results and reference details, order at left...
10.	Tramadol FDA LinkGeneric 11/01/2005 - "Two hours after dosing, moderate-to-severe symptoms that were less common for tramadol/APAP than placebo included photophobia (34.6% vs. 52.2%, P= .003) and phonophobia (34.3% vs. 44.9%, P = .008), but not migraine-related nausea (38.5% vs. 29.4%, P= .681)" 11/01/2005 - "CONCLUSIONS: Tramadol/APAP reduces the severity of pain, photophobia, and phonophobia associated with migraine headache, but does not reduce migraine-associated nausea" Get all the results and reference details, order at left...
57 Drugs and Important Bio-Agents and 85 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Therapies and Procedures

1.	Aftercare (After-Treatment) 07/01/2000 - "Also the reported incidence of accompanying symptoms (nausea, vomiting, photophobia and phonophobia) significantly decreased after treatment" 12/01/1996 - "MAIN OUTCOME MEASURES: Patients rated pain severity, functional ability, headache pain relief, incidence and severity of nausea, and the incidence of vomiting, photophobia, and phonophobia prior to treatment (base-line) and again at 0.5, 1, 2, 3, and 4 hours after treatment" 02/01/2007 - "At 2 to 4 hours and 4 to 24 hours after treatment, the mean intensity of phonophobia and photophobia were significantly lower in the patients treated with almotriptan compared to the placebo-treated patients" 12/11/2000 - "At 2 hours, other migraine headache characteristics, such as functional disability (P =.002), photophobia (P =.02), and phonophobia (P =.08), were significantly improved after treatment with acetaminophen vs placebo" 01/01/2001 - "Rizatriptan was also superior to sumatriptan in terms of the proportions of patients with no nausea, phonophobia or photophobia, and patients with normal function 2 h after treatment intake (p < 0.05)" Get all the results and reference details, order at left...
2.	Hearing Aids (Hearing Aid) 05/01/2008 - "We implemented a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy of TRT as an intervention to improve sound tolerance in hearing-aid eligible persons with hyperacusis andor restricted dynamic ranges" 08/01/2008 - "Two of the experiments used simulations of linear hearing aids, whereas the third used fast-acting multichannel wide-dynamic-range compression and a simulation of loudness recruitment" 06/01/2008 - "Compression is used in hearing aids to compensate for the effects of loudness recruitment" 05/01/2008 - "Hyperacusis is an abnormal condition of sound intolerance that may cause some persons to reject amplified sound from their hearing aids" 05/01/2008 - "Compression is used in hearing aids to compensate for the effects of loudness recruitment" Get all the results and reference details, order at left...
3.	Ear Protective Devices (Earplug) 06/01/2000 - "This paper describes the use of hearing devices that proved to be effective in providing attenuation sufficient that the patient rarely needs to rely on earplugs and earmuffs for relief from his hyperacusis." 01/01/2000 - "The case studies of 14 patients with severe hyperacusis are described; all wore passive attenuators (earplugs and/or earmuffs) in an attempt to alleviate their discomfort, frequently producing communication difficulties" Get all the results and reference details, order at left...
4.	Exercise (Aerobic Exercise) 07/01/2006 - "Furthermore, suggestive or nearly suggestive evidence of linkage to four additional loci was observed with the traits phonophobia (10q22) and aggravation by physical exercise (12q21, 15q14, and Xp21), and, interestingly, these loci have been linked to migraine in previous studies" Get all the results and reference details, order at left...
5.	Stapes Surgery (Stapedectomy) 01/01/2000 - "CONCLUSION: Category loudness scaling appears to be a valuable additional clinical test to characterize postoperative phenomena as distortion of speech and hyperacusis in patients undergoing stapes surgery." 07/01/1970 - "On phonophobia after the stapedectomy operation]" 07/01/1969 - "Phonophobia after stapedectomy." Get all the results and reference details, order at left...
11 Therapies and Procedures and 27 more articles analyzed in the Full Patient-Physician Summary Report, order at left...

Patient-Physician
Research Summary Report
on Hyperacusis

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 24 Outcomes
Top 57 Key Medications
Top 11 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF for "Psoriasis" >>

Price:

$24.00 & Delivery via PDF download,
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>